On December 17, 2025 Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I (Idea to IND), and Valink Therapeutics ("Valink"), a private biotechnology company developing next-generation therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities, reported the formation of a strategic biologics discovery alliance. The collaboration, branded "Biology to Bispecific" (B2B), unites both companies’ complementary platforms and expertise to accelerate the creation of innovative bispecific antibodies and bispecific ADCs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Nona and Valink will combine Nona’s industry-leading Harbour Mice fully human antibodies, including its heavy chain-only antibodies (HCAbs), with Valink’s LiliumX discovery platform to generate and screen thousands of novel drug candidates. With an initial focus on bsADCs in solid tumors, the collaboration will expand Valink’s internal therapeutic pipeline and contribute to future co-development and licensing opportunities.
Previously, Nona Biosciences has supported more than 300 drug discovery programs across multiple therapeutic areas, establishing itself as a leader in biotherapeutics innovation. Now, its extensive antibody repertoire provides a rich library of building blocks for complex biologics.
Valink’s LiliumX technology enables high-throughput generation and functional screening of complex drug candidates from antibody fragments. Further empowered by Nona’s diverse antibody repertoire, LiliumX is uniquely positioned to drive deep exploration of complex biologics, unveiling unexpected targeting strategies and novel target-pair synergies—hallmarks of Valink’s V-gate approach.
Dr. Di Hong, Chief Executive Officer of Nona Biosciences, commented: "We are excited to collaborate with Valink to accelerate the creation of innovative biotherapeutics. By uniting our industry-leading antibody technology platforms and extensive experiences with Valink’s LiliumX discovery engine, we aim to accelerate the pace of bispecific antibody and bsADC discovery and development, ultimately delivering transformative therapies to patients in oncology and beyond."
Dr. Arne Scheu, Chief Executive Officer of Valink Therapeutics, stated: "We are thrilled to form this discovery alliance with Nona – It constitutes a logical and natural expansion of our discovery platform. With Nona, we have found an excellent partner, supercharging our ability to build transformative drugs with which we can meaningfully impact patients’ lives."
(Press release, Nona Biosciences, DEC 17, 2025, View Source [SID1234661506])